Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session.
Zacks Investment Research10/15/2026Neutral
GILD
Gilead Sciences IncNASDAQHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$193.67B
P/E Ratio
—
EPS
$-2.65
Beta
0.33
52W High
$160.51
52W Low
$111.27
50-Day MA
$146.84
200-Day MA
$138.03
Dividend Yield
2.05%
Profit Margin
-10.60%
Forward P/E
15.55
PEG Ratio
2.27
About Gilead Sciences Inc
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Fundamentals
| Revenue (TTM) | $30.46B |
| Gross Profit (TTM) | $24.25B |
| EBITDA | $14.60B |
| Operating Margin | 33.70% |
| Return on Equity | -20.70% |
| Return on Assets | 14.10% |
| Revenue/Share (TTM) | $24.51 |
| Book Value | $9.53 |
| Price-to-Book | 16.00 |
| Price-to-Sales (TTM) | 6.36 |
| EV/Revenue | 6.97 |
| EV/EBITDA | 117.79 |
| Quarterly Earnings Growth (YoY) | 54.80% |
| Quarterly Revenue Growth (YoY) | 10.20% |
| Shares Outstanding | $1.24B |
| Float | $1.24B |
| % Insiders | 0.11% |
| % Institutions | 92.07% |
Historical Volatility
HV 10-Day
28.31%
HV 20-Day
24.77%
HV 30-Day
23.94%
HV 60-Day
25.03%
HV Rank
34.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($159.85 target)
6
Strong Buy16
Buy5
Hold1
Strong SellLatest News
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
Zacks Investment Research10/15/2026Positive
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks Investment Research10/15/2026Positive
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.
Benzinga10/14/2026Positive
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.
24/7 Wall Street10/14/2026Positive
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Gilead shares are up 35% since Barron's highlighted them, but our catalysts have yet to fully play out.
Barrons10/2/2026Positive
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research10/1/2026Positive
NTHM's Index Rebalance Puts Thematic Rotation to Work
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.
ETF Trends9/25/2026Neutral
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
Zacks Investment Research9/21/2026Positive
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research9/17/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GILD and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/17/2026